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Evidence suggests that sexual transmission between men has replaced foreign travel as the 
predominant mode of Shigella transmission in England. However, sexuality and HIV status 
are not routinely recorded for laboratory-reported Shigella, and the role of HIV in the 
Shigella epidemic is not well understood. 
 
Methods 
The Modular Open Laboratory Information System (MOLIS) containing all Shigella cases 
reported to Public Health England (PHE) and the PHE HIV and AIDS Reporting System (HARS) 
holding all adults living with diagnosed HIV in England were matched using a combination of 
Soundex code, date of birth and gender. 
 
Results 
From 2004-2015, 88,664 patients were living with HIV, and 10,269 Shigella cases were 
reported in England; 9% (873/10,269) of Shigella cases were diagnosed with HIV of which 
93% (815/873) were in men. Shigella cases without reported travel history were more likely 
to be living with HIV than those who had travelled (14% (751/5,427) vs. 3% (134/4,854); 
p<0.01). From 2004-2015, the incidence of Shigella in men with HIV rose from 47/100,000 
to 226/100,000 (p<0.01) peaking in 2014 at 265/100,000, but remained low in women 
throughout the study period (0-24/100,000). Among Shigella cases without travel and with 
HIV, 91% (657/720) were men who have sex with men (MSM). HIV preceded Shigella 
diagnosis in 86% (610/720), and 65% (237/362) had an undetectable viral load (<50 
copies/ml). 
 Discussion 
We observed a sustained increase in the national rate of shigellosis in MSM with HIV, who 
may experience more serious clinical disease. Sexual history, HIV status, and sexually 
transmitted infection risk might require sensitive investigation in men presenting with 
gastroenteritis. 
 








The sexual transmission of Shigella was first described in a population with diagnosed HIV in 
the United States in the 1970s1. Since that time, international case-reports and 
epidemiological studies have provided further evidence of sexually transmitted Shigella, in 
particular for Shigella flexneri 3a, S. flexneri 2a, and S. sonnei, and this has been 
predominantly reported among men who have sex with men (MSM)2-5. Sexual behaviour is 
therefore now considered an important risk factor for Shigella6 and, in some instances, this 
is also linked to travel. For example, an outbreak of Shigella among MSM in London in 2006 
coincided with a similar outbreak in Berlin, and the epidemiology suggested that both travel 
and sexual behaviour linked these outbreaks7.  
 
In England, Shigella epidemiology has changed substantially over the past decade. Whereas 
travel associated cases previously predominated, by 2015, more than half of cases were not 
travel associated. There has been a large increase in the number of cases reported in men 
over these years and this is thought due to sexual transmission of Shigella between men7,8. 
Outbreak investigations and case reports have indicated that many of these men might be 
HIV positive8-11.  
 
There are around 35,000 MSM living with diagnosed HIV in England. New HIV diagnoses 
among MSM have risen steadily over the past decade, with 3320 diagnosed in 201512. 
However, sexual identity and HIV status are not routinely recorded for laboratory-reported 
Shigella cases, and the extent to which patients with HIV are affected by Shigella is not well 
understood at a population level. 
 
This study investigated the overlap between Shigella and HIV epidemics in England, by 
linking two public health surveillance datasets (the Modular Open Laboratory Information 
System (MOLIS) and the HIV and AIDS Reporting System (HARS)). Our aim was to 
understand the number of individuals diagnosed with both infections, and explore their 




Shigella reporting in England  
The reporting of Shigella cases in England has been described elsewhere and is summarised 
below7. Faecal specimens from cases with symptoms of gastrointestinal infection are 
submitted to local hospital, private and regional laboratories for culture of potential agents 
including Shigella species8. Local hospital laboratories are recommended to submit 
presumptive strains of S. flexneri and other Shigella species to the Public Health England 
(PHE) national reference laboratory in London, the Gastrointestinal Bacteria Reference Unit 
(GBRU) for confirmation and typing, using standard biochemistry and serological tests8. All 
results reported by laboratories at PHE are recorded in MOLIS, with regular updates and 
duplicate records removed. This study included Shigella cases reported in England from 
2004-2015. 
 
HIV and AIDS reporting in England 
The HIV and AIDS reporting system (HARS) was developed by PHE in conjunction with 
Department of Health and the National Reference Group for HIV, replacing the previously 
used Survey of Prevalent HIV Infections Diagnosed (SOPHID) surveillance system in 2014 and 
incorporating the HIV & AIDS New Diagnoses and Deaths (HANDD) surveillance system13. 
HARS collects comprehensive information covering demographic, service provider, clinic 
attendance, testing history and diagnosis, treatment, clinical information and death. 
Information has been used to understand HIV transmission, plan services, monitor the 
quality of care received by patients and their clinical outcomes13. This study included adults 
(aged >15 years) living with diagnosed HIV in England between 2004 and 2015. 
 
Dataset matching 
A patient-level matching protocol was designed and applied to anonymously match records 
of individuals diagnosed with Shigella between 2004-2015 with records of individuals 
appearing in the HARS dataset between 2004-2015 using a combination of Soundex code, 
date of birth and gender. Cases missing any of these variables were excluded from the 
study. Soundex is a coding system for names based on phonetic spelling that generates an 
anonymous identifier14. The code consists of the first letter of the surname and three digits 




We estimated the proportion of patients diagnosed with Shigella in England between 2004 
and 2015 who were known to be diagnosed with HIV, and stratified the analysis by reported 
travel association, age, gender, and Shigella strain/serotype. The chi-square test was used to 
compare differences between men and women in the proportion with diagnosed HIV  
 
The national cohort of people attending for HIV care was used as the denominator to 
estimate annual rates of Shigellosis among HIV diagnosed persons, and the clinical 
characteristics and timing of diagnoses were described.  
 
The 2015 mid-year population data for England calculated by year of age by the Office of 
National Statistics were used to estimate age-adjusted incidence rates and age adjusted 
incidence rate ratios for men and women.  
 
All analyses were undertaken using STATA statistical software version 13.1. 
 
Results  
From 2004-2015, there were 88,664 adults (aged >15 years) living with diagnosed HIV in England. 
From 2004-2015, 16,244 Shigella cases were reported in England of which 10,269 had adequate 
completion of identifying variables to permit dataset-matching. The 5,975 cases not included in 
the analysis were similar in their gender profile (54% (3220/5975) were male), but were 
more likely to have a travel history associated with their Shigella diagnosis (70% 
(1813/5975).  
 
Overall, 8% (873/10,269) of Shigella cases were identified as living with HIV, of whom 93% 
(715/873) were men, and 15% (815/5,533) of male Shigella cases were living with HIV (Table 
1). Shigella cases without known travel history were more likely than those who had 
travelled to be diagnosed with HIV (14% (751/5,527) vs. 3% (134/4,854); p<0.01). 
 
We focused on non-travel associated Shigella cases, and found that among Shigella cases 
not associated with travel in men, the proportion living with diagnosed HIV varied by 
Shigella species and phage-type, from 16% (242/1,488) for S. sonnei to 31% (190/616) for S. 
flexneri 3a. Among non-travel associated cases of Shigella in men, the proportion with 
diagnosed HIV was 21% (720/3,481), while in women, this proportion was low (2% 
((31/1,946); p<0.01). 
 
Most Shigella cases in individuals living with diagnosed HIV were reported to be MSM in the 
HARS dataset (91% (657/720)). The Shigella diagnosis was found to precede HIV diagnosis in 
14% (100/720), and 65% (237/362) had an undetectable viral load (where available within 3 
months of shigellosis)). 
 
We observed year-on-year increases in Shigella incidence in men living with diagnosed HIV, 
with the rate rising nearly seven-fold from 47 per 100,000 HIV diagnosed population in 2004 
to 226/100,000 in 2015 (p<0.01) peaking in 2014 at 265/100,000 (Table 2), and a similar but 
more pronounced trend among MSM with HIV. Shigella incidence in HIV-positive women 
remained low throughout the study period, and was 6.8/100,000 in 2005 and 19.5/100,000 
in 2015. Overall, age-adjusted incidence rates in individuals diagnosed with HIV were 
estimated to be 4.9 (95% CI 4.5-5.2) per 100,000 in men, and 0.3 (95%CI 0.3-0.4) per 
100,000 in women throughout the study period, with an age-adjusted incidence rate ratio 
between men and women of 14.4 (11.1-19.3).   
 
Discussion 
This study provides a unique insight at a national level into the overlap between Shigella 
and HIV epidemics. Over one fifth of men diagnosed with Shigella without reported travel 
were living with diagnosed HIV, and most were MSM. We observed a sharp year-on-year 
increase in Shigella incidence in men and MSM living with HIV. Around 14% of co-diagnosed 
men were diagnosed with HIV after Shigella, a finding that supports the 2008 UK national 
guidelines for HIV testing which cites Shigella diagnosis as an indicator for HIV testing15. 
 
To date, the role of sexual transmission between men in the Shigella epidemic has been 
largely inferred from gender ratio studies, case series and small epidemiological studies8, 
9,11. Our study adds to this evidence base and suggests that the national increase in Shigella 
incidence in England might be due, at least in part, to Shigella infections in MSM with HIV. 
The observed increase in Shigella incidence in men living with diagnosed HIV is consistent 
with previously noted increases in high-risk sexual behaviours leading to faecal-oral 
transmission among networks of HIV-positive MSM16. During the period under observation, 
there were simultaneous large increases in diagnoses of gonorrhoea, lymphogranuloma 
venereum and other sexually transmitted infections (STI) within the MSM population, 
particularly those living with diagnosed HIV17. Similarities in the characteristics of men 
affected may indicate sexual networking among HIV-diagnosed MSM engaging in HIV 
seroadaptive behaviours, possibly facilitated by geo-spatial apps8. Three social phenomema, 
highlighted in the literature, might be important in driving Shigella transmission and deserve 
further research. These are; (1) sex parties and the use of chemsex, which might influence 
decision-making about risky sexual behaviour19,20,20 , (2) use of social media apps to meet 
previously unknown partners, which might facilitate serosorting practices9, and (3) 
acceptability of sexual practices leading to faecal-oral contact7,9.  
There are also plausible biological explanations for the overlap between Shigella and HIV 
epidemics, including increased shedding of Shigella species, a prolonged infectious period, 
and increased susceptibility to Shigella in people living with HIV16.  While our data suggest 
that most MSM with HIV and Shigella were not clinically immunosuppressed, HIV might still 
affect immunological responses to Shigella, increasing the severity of clinical disease and 
duration of infectiousness21. 
We observed a small number of Shigella diagnoses in women living with diagnosed HIV. 
However, the extent to which heterosexual sex, including heterosexual sex between MSM 
and women, has a role in Shigella transmission remains an area for further research. 
 
The key strength of this study is the linking of two national datasets to estimate the 
proportion of individuals diagnosed with Shigella and living with HIV, allowing year on year 
comparisons to be made. However, patients with mild gastrointestinal symptoms might not 
seek attention from health services, leading to incomplete Shigella case ascertainment and 
underestimation of Shigella incidence. There might also be bias introduced by under-
reporting of same sex behaviour in HIV databases, such that Shigella incidence in MSM may 
be under-estimated. The matching protocol used key variables to enable individual-level 
matching, which might generate false positive and false negative matches, and our study 
might underestimate the true number of Shigella diagnoses in people living with HIV due to 
cases excluded from the study with incomplete identifying variables, and because an 
estimated 17% of people living with HIV are unaware of their infection22. We also recognise 
that neither the health consequences of Shigella infection nor the antimicrobial 
susceptibility of Shigella isolates are reported here, which might assist in understanding the 
impact on health services and the implications for people living with HIV. Nevertheless, 
overall, our study is likely to have under- rather than overestimated the extent to which HIV 
and Shigella epidemics have overlapped. 
 
This study has important and immediate clinical and public health implications, highlighting 
the need for clinicians to consider and test for enteric pathogens such as Shigella in men 
presenting with gastrointestinal symptoms, who might not disclose male partners, and for 
increased awareness about Shigella amongst MSM, particularly those living with HIV 
infection. Sexual history, HIV status, and sexually transmitted infection risk might require 
sensitive investigation in men presenting with gastrointestinal symptoms and/or Shigella. 
 
Key messages  
·      We used national surveillance datasets for HIV and Shigella to investigate the role of 
HIV in the recent Shigella epidemic in England. 
-      Shigella cases without reported travel history were most likely to be living with HIV 
(14%) 
·      Among cases of Shigella without travel history and diagnosed with HIV, 91% were 
reported to be men who have sex with men (MSM).  
·      In most cases, HIV preceded the Shigella diagnosis and for most patients with HIV, 
the most recent viral load was undetectable.  
·      These data emphasise the importance of sensitively asking about sexual history, HIV 
status, and sexually transmitted infections in men presenting with gastrointestinal 
symptoms and/or Shigella.  
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Table 1. Shigella diagnoses by HIV status in England between 2004 and 2015, stratified by sex and travel 
association 
  
All Shigella diagnoses Male (%) Female (%) Total (%) P value  
HIV positive 815 (15) 58 (1) 873 (8) <0.01 
HIV negative/status unknown 4718 (85) 4678 (99) 9396 (92)  
 Total 5533 (100) 4736 (100) 10269 (100)  
Non-travel associated Shigella 
diagnoses 
    
HIV positive 720 (21) 31 (2) 751   (14) <0.01 
HIV negative/status unknown 2761 (79) 1915 (98) 4676 (86)  
Total 3481 (100) 1946 (100)  5427 (100)  
Travel associated Shigella 
diagnoses 
    
HIV positive 95 (5) 27 (1) 134 (3) <0.01 
HIV negative/status unknown 1957 (95) 2763 (99) 4720 (97)  
 Total 2052 (100) 2790 (100) 4854  (100)  
Non travel associated Shigella 
diagnoses 
    
S.flexneri 2a     
HIV positive 192 (26) 8(4) 200 (21) <0.01 
HIV negative/status unknown 543 (74) 195 (96) 738 (79)  
Total 735 (100) 203 (100) 938 (100)  
S.flexneri 3a     
HIV positive 190 (31) 6 (7) 196 (28) <0.01 
HIV negative/status unknown 426 (69) 80 (93) 506 (72)  
 Total 616 (100) 86 (100) 702 (100)  
S.Sonnei     
 HIV positive 242 (16) 6 (1) 244 (10) <0.01 
 HIV negative/status unknown 1246 (84) 1113 (99) 2359 (90)  
 Total 1488 (100) 1119 (100) 2537 (100)  
Other Shigella     
HIV positive 96 (15) 11 (2) 107  (7) <0.01 
HIV negative/status unknown 546 (85) 927 (98) 1473 (93)  
 Total 642 (100) 1473 (100) 1580 (100)  
Non travel associated Shigella 
diagnoses 
    
Age 16-20     
HIV positive 6 (5) 0 (0) 6 (2) 0.01 
HIV negative/status unknown 115 (95) 121 (100) 236 (98)  
Total 121 (100) 121 (100) 242 (100)  
Age 21-40     
HIV positive 399 (19) 21 (2) 420 (13) <0.01 
HIV negative/status unknown 1655 (81) 1161 (98) 2816(87)  
 Total 2054 (100) 1182 (100) 3236(100)  
Age 41-60     
 HIV positive 311 (24) 15 (2) 326 (20) <0.01 
 HIV negative/status unknown 996 (76) 628 (98) 1624 (80)  
 Total 1307 (100) 643 (100) 1950 (100)  
 Table 2. Shigella diagnoses and rates in HIV positive individuals with no travel association between 2004 and 2015 
 
a) Shigella diagnoses and rates in HIV positive men with no travel association 
 
Year of Shigella 
Diagnosis 
Shigella cases in HIV 
positive men 
Adults seen for HIV 
care in England 
Shigella rate per 100000 HIV 
diagnosed population 
Shigella incidence rate ratio* 
 
2004 12 25,384 47.3 1 
2005 12 28,051 42.8 0.90 
2006 16 30,951 51.7 1.09 
2007 25 33,856 73.8 1.56 
2008 26 36,650 70.9 1.50 
2009 38 39,391 96.5 2.04 
2010 57 41,933 135.9 2.87 
2011 61 44,668 136.6 2.89 
2012 84 47,436 177.1 3.74 
2013 124 49,959 248.2 5.25 
2014 140 52,913 264.6 5.59 
2015 125 55,391 225.7 4.77 
  * Shigella incidence in 2004 used as baseline 
 
b) Shigella diagnoses and rates in HIV positive adult MSM with no travel association 
 
Year of Shigella 
Diagnosis 
Shigella cases in HIV 
positive MSM 
MSM seen for HIV 
care in England 
Shigella rate per 100000 HIV 
diagnosed population 
Shigella incidence rate ratio* 
 
2004 10 16741 59.7 1 
2005 9 18407 48.9 0.82 
2006 14 20219 69.2 1.16 
2007 22 22103 99.5 1.67 
2008 21 23797 88.2 1.48 
2009 35 25540 137.0 2.30 
2010 52 27414 189.7 3.18 
2011 56 29278 191.3 3.20 
2012 79 31321 252.2 4.22 
2013 112 33109 338.3 5.67 
2014 130 35407 367.2 6.15 
2015 117 37215 314.4 5.27 
  * Shigella incidence in 2004 used as baseline 
 
c) Shigella diagnoses and rates in HIV positive women with no travel association 
 
Year of Shigella 
Diagnosis 
Shigella cases in HIV 
positive women 
Adults seen for HIV 
care in England 
Shigella rate per 100000 HIV 
diagnosed population 
Shigella incidence rate ratio* 
 
2004 0 12,639 0.0 0.00 
2005 1 14,779 6.8 1.00 
2006 6 16,521 36.3 5.34 
2007 3 17,923 16.7 2.46 
2008 3 19,516 15.4 2.26 
2009 2 20,633 9.7 1.43 
2010 2 21,708 9.2 1.35 
2011 0 22,854 0.0 0.00 
2012 1 23,749 4.2 0.62 
2013 6 24,335 24.7 3.63 
2014 2 25,326 7.9 1.16 
2015 5 25,671 19.5 2.87 
 * Shigella incidence in 2005 used as baseline 
 
